Abstract
Leishmaniasis affects the poorest of the poor across the globe. The present treatment is not quite effective. The troubling increase in drug resistance and the inaccessibility of an effective Leishmania vaccine requires a study to find new targets or biomarkers for effective therapy. Advancements in emerging technology bring some new hope in its detection, care, and regulation. In parasitological research, the DNA microarray technique is now commonly used to promote the consideration of disease mechanisms and the recognition of drug targets and biomarkers for diagnostic and therapeutic progress. Due to the inherent nature of experimental workflows, access, expense, and sophistication of data obtained, functional analysis and interpretation of microarray outcomes remains very difficult. The use of curate microarray information in the case of leishmaniasis for the identification of the therapeutic target and biomarker and their selection/implementation in clinical use has been clarified and emphasized.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Pathogenesis, Treatment and Prevention of Leishmaniasis
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
